- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Giora Sharf Discusses Intentional, Unintentional Nonadherence in CML Patients
Although there is a clear link between nonadherence and outcomes of a patient with chronic myelogenous leukemia (CML), some patient intentionally stop taking their medication, said Giora Sharf, co-founder of the CML Advocates Network.
Although there is a clear link between nonadherence and outcomes of a patient with chronic myelogenous leukemia (CML), some patient intentionally stop taking their medication, said Giora Sharf, co-founder of the CML Advocates Network.
Some patients are unintentionally not adhering to their medication, sometimes because they simply forget, which the CML Advocates Network hopes combat through its new app.
However, there are times patients choose intentional nonadherence, often because the patient does not want to suffer from the side effects of the medication. Another dangerous barrier is when a patient feels fine, and stops treatment because he or she doesn’t see the point in taking it, Mr Sharf explained.
